

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

Miso Kim,^{1,2} Jeong-Ok Lee,³ Jiwon Koh,⁴ Tae Min Kim,^{1,2} Ji Yun Lee,³ Yoon Kyung Jeon,^{2,4} Bhumsuk Keam,^{1,2} Dong-Wan Kim,^{1,2} Jong Seok Lee³ and Dae Seog Heo^{1,2}

¹Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; ²Seoul National University Cancer Research Institute, Seoul, Republic of Korea; ³Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea and ⁴Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.

Correspondence: TAE MIN KIM - gabriel9@snu.ac.kr

doi:10.3324/haematol.2021.278301

Supplementary Tables

Supplementary Table S1. Patients' characteristics

Characteristics	No. of patients (%)
Age	Median 67 (range, 38–87 years)
≤ 60 years	11 (78.6)
> 60 years	14 (21.4)
Sex	
Male	20 (80.0)
Female	5 (20.0)
Diagnosis	
EBV-positive mature T/NK-cell neoplasms	
Angioimmunoblastic T-cell lymphoma	10 (40.0)
EBV-positive peripheral T-cell lymphoma, NOS	5 (20.0)
Extranodal NK-/T-cell lymphoma, nasal type	4 (16.0)
Hydroa vacciniform-like T-cell lymphoma	1 (4.0)
Mycosis fungoides	1 (4.0)
EBV-positive T-cell LPDs	1 (4.0)
EBV-positive mature B-cell neoplasms	
EBV-positive DLBCL of the elderly	2 (8.0)
B cell lymphoma, unclassifiable, with features intermediate between DLBCL and cHL	1 (4.0)
CD30 expression	
Low (1 – <10%)	13 (52.0)
Intermediate (10 – <50%)	5 (20.0)
High (≥ 50%)	7 (28.0)
Ann Arbor stage at initial diagnosis	

II	1 (4.0)
III	7 (28.0)
IV	17 (68.0)
ECOG Performance status	
0	2 (8.0)
1	23 (92.0)
IPI scores	
0–1	6 (24.0)
2	7 (28.0)
3	7 (28.0)
4–5	5 (20.0)
Prior lines of therapy	
1	10 (40.0)
2	9 (36.0)
≥3	6 (24.0)

Abbreviations: EBV, Epstein-Barr virus; DLBCL, diffuse large B-cell lymphoma; cHL, classical Hodgkin lymphoma; LPD, lymphoproliferative disorder; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index

Supplementary Table S2. Treatment-related Adverse Events

Toxicities	Total N (%)	Grade 1	Grade 2	Grade 3	Grade 4
Peripheral neuropathy	12 (48)	8	4	0	0
Neutropenia	10 (40)	0	5	3	2
Thrombocytopenia	5 (20)	0	2	1	2
Rash	4 (16)	3	1	0	0
Alopecia	3 (12)	3	0	0	0
Fatigue	3 (12)	3	0	0	0
Anemia	2 (8)	0	0	2	0
Decreased appetite	2 (8)	2	0	0	0
Pruritus	2 (8)	1	1	0	0
Diarrhea	1 (4)	0	1	0	0
Dizziness	1 (4)	1	0	0	0
Hyperglycemia	1 (4)	1	0	0	0
Epigastric discomfort	1 (4)	1	0	0	0
Asthenia	1 (4)	1	0	0	0
Pneumonitis	1 (4)	1	0	0	0
Headache	1 (4)	1	0	0	0
Nail change	1 (4)	1	0	0	0
Nausea	1 (4)	1	0	0	0
Urinary retention	1 (4)	1	0	0	0
Sore throat	1 (4)	1	0	0	0
Thirst	1 (4)	1	0	0	0

Supplementary Figures

Figure S1. Kaplan-Meier plots for (A) progression-free survival, (B) overall survival, (C) progression-free survival according to soluble CD30, and (d) overall survival according to soluble CD30.

Figure S1 (A)




Figure S1 (B)




Figure S1 (C)




Figure S1 (D)

